Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Abstract

This is the authors' abstract. We don't add key points for this paper.

MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.

No takes yet. Share an insight, caveat, or question.

Aggarwal et al. (2022) studied this question.

View Full Paper

Ask AI

Bookmark

This is the authors' abstract. We don't add key points for this paper.

MEDI0457 plus durvalumab was well tolerated. While the primary efficacy endpoint was not reached, clinical benefit was encouraging.